Skip to main content

Table 1 Clinical trials and condition of PRMT, EZH2, LSD1, HDAC and DNMT1 inhibitors

From: Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy

Category Drug NCT number Study title Condition Status Phase
PRMT inhibitors GSK3368715 NCT03666988 First Time in Humans (FTIH) Study of GSK3368715 in Participants with Solid Tumors and DLBCL Neoplasms Recruiting Phase 1
GSK3326595 NCT02783300 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Neoplasms Recruiting Phase 1
NCT03614728 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and AML Neoplasms Recruiting Phase 1
EZH2 inhibitors Tazemetostat NCT02860286 Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma Mesothelioma, BAP1 Loss of Function Completed Phase 2
NCT02220842 A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and DLBCL Lymphoma Completed Phase 1
NCT03010982 Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B Cell Lymphomas or Adv Solid Tumors Several Types of Lymphoma, Advanced Solid Tumors Completed Phase 1
CPI-1205 NCT02395601 A Study Evaluating CPI-1205 in Patients With B Cell Lymphomas B Cell Lymphoma Completed Phase 1
GSK2816126 NCT02082977 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory DLBCL, Transformed Follicular Lymphoma, Other NHLs, Solid Tumors and MM Cancer, Neoplasms Terminated Phase 1
LSD1 inhibitors GSK2879552 NCT02034123 Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma (SCLC) SCLC Terminated Phase 1
NCT02929498 Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk MDS MDS Terminated Phase 1/2
NCT02177812 A Phase I Dose Escalation Study of GSK2879552 in Subjects With AML AML Terminated Phase 1
Tranylcypromine (TCP) NCT02273102 Study of TCP-ATRA for Adult Patients With AML and MDS AML, MDS Completed Phase 1
NCT02261779 Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible AML Unknown Phase 1/2
NCT02717884 Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With TCP AML, MDS Recruiting Phase 1/2
HDAC inhibitors Vorinostat NCT00918489 Study on Efficacy and Tolerability of Virinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) (SAHA-I) STS Completed Phase 2
NCT00735826 A Clinical Trial to Validate Molecular Targets of Virinostat in Patients With Aerodigestive Tract Cancer Aerodigestive Tract Cancer, Lung Cancer, Esophageal Cancer, Head and Neck Cancer Completed Not Applicable
Abexinostat NCT03592472 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Renal Cell Carcinoma Active, not recruiting Phase 3
Panobinostat NCT01336842 Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Solid Tumors, NSCLC Completed Phase 1
DNMT1 inhibitors 5'-Azacytidine (azacytidine) NCT02940483 Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma (5-AZA) Brain Tumor Recurrent Completed Early Phase 1
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With AML Who Are Ineligible for Standard Induction Therapy AML Active, not recruiting Phase 3
Decitabine NCT02957968 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Breast Cancer Recruiting Phase 2
NCT04252248 Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage Head and Neck Cancer, Anogenital Cancer Recruiting Phase 1
NCT02961101 Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies Multiple Malignancies Recruiting Phase 1/2